← Browse by Condition
Medical Condition

neoadjuvant therapy

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for neoadjuvant therapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neoadjuvant therapy Clinical Trials

How many clinical trials are currently recruiting for neoadjuvant therapy?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for neoadjuvant therapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neoadjuvant therapy?
neoadjuvant therapy research spans Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neoadjuvant therapy clinical trial?
Eligibility criteria for neoadjuvant therapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
2
Top Sponsors
Xijing Hospital 1 trial
Beijing Tongren Hospital 1 trial
German Cancer Research Center 1 trial
Beijing Chao Yang Hospital 1 trial
Fudan University 1 trial

Recruiting Clinical Trials

NCT06613165
Recruiting
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
Enrollment
100 pts
Location
China
Sponsor
Xijing Hospital
View Trial →
NCT06102395 Phase 3
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Enrollment
272 pts
Location
China
Sponsor
Beijing Tongren Hospital
View Trial →
NCT05906407
Recruiting
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
Enrollment
2,000 pts
Location
Germany
Sponsor
German Cancer Research Center
View Trial →
NCT04743102
Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Enrollment
260 pts
Location
China
Sponsor
Beijing Chao Yang Hospital
View Trial →
NCT07541664
Recruiting
Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
Enrollment
66 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06949033 Phase 3
Recruiting
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment
668 pts
Location
China
Sponsor
Zuoyi Jiao
View Trial →
NCT07388771
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)
Enrollment
500 pts
Location
China
Sponsor
Qian Chu
View Trial →

Related Conditions

immune related adverse event (1) dmmr colorectal cancer (1) head and neck squamous cell carcinoma (1) pembrolizumab (1) early stage breast cancer (1) rectal cancer (1) complete remission (1) metastasis (1) gastric cancer including stomach and gastroesophageal junction gej (1) adjuvant chemotherapy (1) pcr rate (1) mpr (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology